Key insights
- Eli Lilly's VERVE-102 showed promising results in reducing PCSK9 and LDL-C levels with a single dose, suggesting a potential one-time treatment for hypercholesterolemia. This breakthrough could significantly impact the healthcare sector and improve longevity, positively influencing investor sentiment towards LLY and potentially other gene therapy companies.
"A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia"
Forget the stock price, the implications for increase in longevity for a big chunk of the population is huge! Hope the next stage of trials goes through smoothly. This is big.
"They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol. That means they'll be able to effectively prevent most heart disease with a single infusion!", per an expert.